Market Overview

Hemispherx Biopharma Announces IRB Approval Of Clinical Study in Metastatic Triple Negative Breast Cancer In Collaboration With Roswell Park Comprehensive Cancer Center

Related HEB
How The Ultra-Wealthy Are Helping Advance Health And Life Sciences
Money Is Energy: A Profile Of Family Office And Silk Legend Thomas Gütermann

Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today Roswell Park Comprehensive Cancer Center Institutional Review Board ("IRB") approval and shipment of Ampligen to start an oncology clinical study combining its dsRNA TLR3 agonist Ampligen with Merck's Keytruda (pembrolizumab) in Metastatic Triple Negative Breast Cancer. The study will enroll at least six participants and be conducted by Drs. Mateusz Opyrchal and Pawel Kalinski at Roswell Park, a National Cancer Institute-designated comprehensive cancer center in Buffalo, New York.

Posted-In: News FDA


Related Articles (HEB)

View Comments and Join the Discussion!

Molina Wins New Bulls On Cost Saving, Margin Opportunities

'Heathrow suspends all flights due to 'drone sighting'' -The Telegraph